{"id":909266,"date":"2025-11-12T17:42:08","date_gmt":"2025-11-12T22:42:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/"},"modified":"2025-11-12T17:42:08","modified_gmt":"2025-11-12T22:42:08","slug":"maxcyte-announces-planned-cfo-transition-in-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/","title":{"rendered":"MaxCyte Announces Planned CFO Transition in 2026"},"content":{"rendered":"

\nCompany initiates search for successor
\n<\/h2>\n
\n

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc.<\/u><\/a>, (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Chief Financial Officer Douglas Swirsky has informed the Company of his decision to transition from his role in the first half of 2026. Mr. Swirsky and the Company are working closely to ensure a smooth and orderly transition, and he will remain Chief Financial Officer until a successor has been appointed. The Company has initiated a structured search process to identify Mr. Swirsky\u2019s successor. Following the transition period, Mr. Swirsky will continue in an advisory capacity to support strategic initiatives and ensure continuity.\u00a0\u00a0<\/p>\n

\u201cDoug has been an exceptional partner to MaxCyte, having played a key role in advancing our strategy, strengthening our team, and enhancing our capabilities,\u201d said Maher Masoud, Chief Executive Officer. \u201cWe appreciate Doug\u2019s decision to provide ample notice and flexibility for a thoughtful and orderly transition.\u201d<\/p>\n

\u201cIt\u2019s been a privilege to serve as CFO of MaxCyte,\u201d said Douglas Swirsky. \u201cAfter thoughtful consideration, Maher and I have agreed that this is the right time for me to transition from MaxCyte. I\u2019m incredibly proud of what we\u2019ve accomplished together and confident in the Company\u2019s continued success under Maher. I look forward to supporting a seamless handoff to my successor.\u201d<\/p>\n

The transition is not expected to impact the Company\u2019s operations, results, financial reporting cadence or strategic priorities.<\/p>\n

\n About MaxCyte<\/strong>\n <\/p>\n

At MaxCyte\u00ae, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation\u00ae technology and SeQure DX\u2122 gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com<\/a> and follow us on X<\/a> and LinkedIn<\/a>.<\/p>\n

\n MaxCyte Contacts:<\/strong>\n <\/p>\n

\n Investor Relations<\/strong>
\n
\n
\n Gilmartin Group<\/em>
\n <\/strong>
\n
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
\n
\n Oak Street Communications<\/em>
\n <\/strong>
\n
Kristen White
kristen@oakstreetcommunications.com<\/u><\/a>
415.608.6060<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company initiates search for successor ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Chief Financial Officer Douglas Swirsky has informed the Company of his decision to transition from his role in the first half of 2026. Mr. Swirsky and the Company are working closely to ensure a smooth and orderly transition, and he will remain Chief Financial Officer until a successor has been appointed. The Company has initiated a structured search process to identify Mr. Swirsky\u2019s successor. Following the transition period, Mr. Swirsky will continue in an advisory capacity to support strategic initiatives … <\/p>\n

Continue reading “MaxCyte Announces Planned CFO Transition in 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-909266","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMaxCyte Announces Planned CFO Transition in 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaxCyte Announces Planned CFO Transition in 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company initiates search for successor ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Chief Financial Officer Douglas Swirsky has informed the Company of his decision to transition from his role in the first half of 2026. Mr. Swirsky and the Company are working closely to ensure a smooth and orderly transition, and he will remain Chief Financial Officer until a successor has been appointed. The Company has initiated a structured search process to identify Mr. Swirsky\u2019s successor. Following the transition period, Mr. Swirsky will continue in an advisory capacity to support strategic initiatives … Continue reading "MaxCyte Announces Planned CFO Transition in 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T22:42:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NDQ2OSM3MjYwNTI5IzIyMDUxNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MaxCyte Announces Planned CFO Transition in 2026\",\"datePublished\":\"2025-11-12T22:42:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/\"},\"wordCount\":390,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NDQ2OSM3MjYwNTI5IzIyMDUxNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/\",\"name\":\"MaxCyte Announces Planned CFO Transition in 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NDQ2OSM3MjYwNTI5IzIyMDUxNzg=\",\"datePublished\":\"2025-11-12T22:42:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NDQ2OSM3MjYwNTI5IzIyMDUxNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NDQ2OSM3MjYwNTI5IzIyMDUxNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-planned-cfo-transition-in-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaxCyte Announces Planned CFO Transition in 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaxCyte Announces Planned CFO Transition in 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/","og_locale":"en_US","og_type":"article","og_title":"MaxCyte Announces Planned CFO Transition in 2026 - Market Newsdesk","og_description":"Company initiates search for successor ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Chief Financial Officer Douglas Swirsky has informed the Company of his decision to transition from his role in the first half of 2026. Mr. Swirsky and the Company are working closely to ensure a smooth and orderly transition, and he will remain Chief Financial Officer until a successor has been appointed. The Company has initiated a structured search process to identify Mr. Swirsky\u2019s successor. Following the transition period, Mr. Swirsky will continue in an advisory capacity to support strategic initiatives … Continue reading \"MaxCyte Announces Planned CFO Transition in 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-12T22:42:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NDQ2OSM3MjYwNTI5IzIyMDUxNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MaxCyte Announces Planned CFO Transition in 2026","datePublished":"2025-11-12T22:42:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/"},"wordCount":390,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NDQ2OSM3MjYwNTI5IzIyMDUxNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/","name":"MaxCyte Announces Planned CFO Transition in 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NDQ2OSM3MjYwNTI5IzIyMDUxNzg=","datePublished":"2025-11-12T22:42:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NDQ2OSM3MjYwNTI5IzIyMDUxNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NDQ2OSM3MjYwNTI5IzIyMDUxNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-planned-cfo-transition-in-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MaxCyte Announces Planned CFO Transition in 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/909266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=909266"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/909266\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=909266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=909266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=909266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}